Methods and compositions for treatment of cancer

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11339213
APP PUB NO 20190023776A1
SERIAL NO

15762117

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly colorectal, ovarian (e.g., platinum-resistant ovarian), pancreatic, and endometrial cancers. Also provided are methods, compositions, and kits for treatment of tumors or cancer using combinations that include a VEGF/DLL4 bispecific agent and one or more chemotherapeutic agents (e.g., leucovorin, 5-fluorouracil, and irinotecan; paclitaxel; gemcitabine and ABRAXANE® (albumin-bound paclitaxel for injectable suspension); and paclitaxel and carboplatin). The present invention further provides methods of using the agents or combinations of agents to inhibit growth of a colorectal, ovarian, pancreatic, or endometrial tumor. Also described are methods of treating cancer, particularly colorectal, ovarian, pancreatic, and endometrial cancer, comprising administering a therapeutically effect amount of an agent, antibody, or therapeutic combination of the present invention to a patient having a tumor or cancer.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • MEREO BIOPHARMA 5, INC.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dupont, Jakob Hillsborough, US 29 170
Parmar, Hema San Mateo, US 4 3
Stagg, Robert Joseph Moraga, US 13 116

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Nov 24, 2025
7.5 Year Payment $3600.00 $1800.00 $900.00 Nov 24, 2029
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 24, 2033
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00